Drug facts

Tirzepatide while breastfeeding

Reviewed August 2026

What section 8.2 actually reports¹

The section has two parts, a risk summary and the data behind it. The risk summary says the concentration of tirzepatide in breast milk was found to be either undetectable or low compared with the maternal administered dose. The data paragraph gives the study.

That is the whole of it, at the label’s own precision. Nothing above has been rounded off, carried further than the study went, or turned into a sentence the label does not support.

What section 8.2 does not say¹

This is the more useful half of the page, because the gaps are specific and the internet fills them confidently.

• It was a single dose. Eleven women, one 5 mg dose, a 28-day sampling window. Nothing on the label describes what happens in milk with once-weekly dosing continued over months.
• No data on the breastfed infant. The label states this in those words. Not reassuring data, not concerning data — none.
• No data on milk production. Same sentence, same status.
• No recommendation either way. Section 8.2 does not advise against breastfeeding and does not endorse it. It sets out a weighing: the developmental and health benefits of breastfeeding, the mother’s clinical need for the drug, and any potential adverse effects on the infant from the drug or from the underlying maternal condition.

A weighing is not an answer, and it is addressed to a clinician. That is who this question ends with.

The Medication Guide says the same thing in fewer words²

The plain-language guide bound to the label puts it this way: tell your healthcare provider if you are breastfeeding or plan to breastfeed; the drug may pass into your breast milk; talk to your healthcare provider about the best way to feed your baby while using it.

“May pass into your breast milk” and “undetectable in 164 of 171 samples” are the same finding at two resolutions, not two different claims. Seven samples out of 171 did contain measurable drug. The plain-language sentence is written around those seven.

The lactation study does not appear to be published³

It does not turn up in PubMed. Tirzepatide together with “breast milk” in the title or abstract returns no records; tirzepatide together with “milk” returns two, both unrelated — one on milk-derived vesicles as a delivery vehicle, one on transgenic mice. Tirzepatide together with “lactation” returns eleven records, and none of them is a report of this study.

So the label is the source, and as far as we can establish today it is the only source. That is worth knowing before you weigh a page that cites “the research” on this question against one that cites section 8.2.

Pregnancy is a different section with a different answer⁴

Searches for these two topics run together, and the label treats them very differently. Section 8.1 states that weight loss offers no benefit to a pregnant patient and may cause fetal harm, and advises that pregnant patients be told weight loss is not recommended during pregnancy and to discontinue the drug when a pregnancy is recognized. There is also a pregnancy exposure registry run by the manufacturer.

Section 8.3 adds a related point that surprises people: because the drug delays gastric emptying, it may reduce the effectiveness of oral hormonal contraceptives, and the label advises switching to a non-oral method or adding a barrier method for four weeks after starting and for four weeks after each increase in dose.

That contraception statement is a labeling instruction, and it belongs on a page about feeding and fertility even though people rarely go looking for it here. It is not advice from us, and the timing questions it raises belong to a prescriber.

What a compounded vial changes¹

No lactation study exists for any compounded preparation, and the concentration in a compounded vial is set by the pharmacy rather than by an approved specification — which is one of the real differences between a compounded vial and Zepbound. Section 8.2’s numbers describe the approved product and are not transferable.

Where to take this⁵

To a prescriber, and to whoever is caring for the baby. This is the page on this site where the gap between what the label establishes and what a person actually needs to decide is widest, and no amount of careful reading closes it. If you are weighing the wider risk picture, the label’s reactions reported in 5% or more of participants and the boxed warning and the contraindications that follow from it are the other two places to look.

Pregnancy and the contraception window are set out separately: what sections 8.1 and 7.2 say →